Journal
JOURNAL OF PHYSICAL CHEMISTRY B
Volume 119, Issue 14, Pages 4831-4841Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.jpcb.5b00692
Keywords
-
Categories
Funding
- National Institutes of Health [R01AG047116]
- UCLA Jim Easton Consortium for Drug Discovery and Biomarker Development
- National Science Foundation [DMR-0805148]
- NSF [DMR 1121053]
Ask authors/readers for more resources
The early oligomerization of amyloid beta-protein (A beta) has been shown to be an important event in the pathology of Alzheimer's disease (AD). Designing small molecule inhibitors targeting A beta oligomerization is one attractive and promising strategy for AD treatment. Here we used ion mobility spectrometry coupled to mass spectrometry (IMS-MS) to study the different effects of the molecular tweezers CLR01 and CLRO3 on A beta self assembly CLR01 was found to bind to A beta directly and disrupt its early oligornerization. Moreover, CLR01 remodeled the early oligomerization of A beta 42 by compacting the structures of dimers and tetramers and as a consequence eliminated higher order oligomers. Unexpectedly, the negative control derivative, CLR03, which lacks the hydrophobic arms of the tweezer structure, was found to facilitate early A beta oligomerization. Our study provides an example of IMS as a powerful tool to study and better understand the interaction between small molecule modulators and A beta oligomerization, which is not attainable by other methods, and provides important insights into therapeutic development of molecular tweezers for AD treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available